Cancer
Performance Capabilities
Driving Cutting-Edge Science
Geneva researchers have experience in developing biologics and cancer therapeutics, with expertise in areas including:
- Basic research
- Bioinformatic analysis
- Biomarker discovery
- Bioprinting
- Cancer biology
- Clinical cancer drugs
- Clinical trials
- Diagnostic testing
- Genome-wide analysis
- Immunotherapy
- IND support
- Personalized medicine
- Population-based research
- Preclinical research
- Prognostic markers
- Translational research
Geneva Expertise
Featured Researcher
Curtis Harris, MD
Dr. Harris, a scientist at NCI, has conducted research that has spanned more than half a century, making significant breakthroughs in cancer research.
DECAMP Consortium
The Detection of Early Lung Cancer Among Military Personnel (DECAMP) Consortium is a multidisciplinary and translational research program intended to improve early detection of lung cancer through non-invasive biomarkers and improved screening. DECAMP 1 and 2 studies are funded through the DoD Lung Cancer Research Program, Johnson and Johnson Inc., and Novartis Biomedical Research Institutes.
Read More![](https://genevausa.org/wp-content/uploads/2021/01/research-indicators-icon.png)
Research Indications
Geneva has diverse experience in managing oncology programs in areas including:
Bladder Cancer
Brain Metastases
Breast Cancer
Childhood Cancers
Follicular Lymphoma
Glioblastoma
Head and Neck Cancer
Leukemia
Lung Cancer
Mantle Cell Lymphoma
Metastatic Colorectal Cancer
Neoplasms
Neuroblastoma
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Prostate Cancer
Rare Cancers
Small Cell Carcinoma
Tumors